New Insights Into Stroke in Chronic Kidney Disease

Advances in Chronic Kidney Disease

Volumn 15, Issue 4, 2008, Pages 338-346

  Khella, Sami L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiplatelet drugs; Cerebrovascular accident; Chronic kidney disease; Hypertension; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIALYSIS; DISEASE PREDISPOSITION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMORRHAGIC STROKE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; STENT; STOMACH DISEASE; STOMACH TOXICITY; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STROKE; SURVIVAL ANALYSIS;

EID: 52049116908     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.07.002     Document Type: Article

References (73)

1. Khella S.L., and Bleicher M.B. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol 2 (2007) 1343-1351
2. Bos M.J., Koudstaal P.J., Hofman A., et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke. The Rotterdam Study. Stroke 38 (2007) 3127
3. Koren-Morag N., Goldbourt U., and Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 67 (2006) 224-228
4. Weiner D.E., Tighiouart H., Amin M.G., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15 (2004) 1307-1315
5. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
6. McCullough P.A., Li S., Jurkovitz C.T., et al. Chronic kidney disease and cardiovascular disease in volunteer and randomly selected populations: KEEP and NHANES. Am J Kidney Dis 51 (2008) B68-B68
7. Weiner D.E., Tighiouart H., and Stark P.C. Kidney disease is a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 44 (2004) 198-206
8. Abramson J.L., Jurkvitz C.T., Vaccarino V., et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC study. Kidney Int 64 (2003) 610-615
9. Nakayama M., Metoki H., Terawak H., et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-The Ohasama study. Nephrol Dial Transplant 22 (2007) 1910-1915
10. van der Sande F.M., Hermans M.M., Leunissen K.M., et al. Noncardiac consequences of hypertension in hemodialysis patients. Semin Dial 17 (2004) 304-306
11. Aull-Watschinger S., Konstantin H., Demetriou D., et al. Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant 23 (2007) 1429-1435
12. Oliveras A., Roquer J., Puig J.M., et al. Stroke in renal transplant recipients: Epidemiology, predictive risk factors and outcome. Clin Transplant 17 (2003) 1-8
13. Caplan L.R., Gorelick P., and Hier D. Race, sex, and occlusive cerebrovascular disease: A review. Stroke 17 (1986) 648-655
14. Mohr J.P., Caplan L.R., and Melski J.W. The Harvard Cooperative Stroke Registry: A prospective registry. Neurology 28 (1978) 754-762
15. Seliger S.L., Gillen D.L., Longstreth Jr. W.T., et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64 (2003) 603-609
16. Toyoda K., Fujii K., Fujimi S., et al. Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am J Kidney Dis 45 (2005) 1058-1066
17. Savitz S.I., and Caplan L.R. Vertebrobasilar disease. N Engl J Med 352 (2005) 2618-2626
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2987
19. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 (1997) 739-745
20. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
21. Hansson L., Lithell H., Skoog I., et al. Study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. Blood Press 8 (1999) 177-183
22. Bosch J., Yusuf S., Pogue J., et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 324 (2002) 699-702
23. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
24. Staessen J.A., and Wang J.G. Birkenhäger WH: Outcome beyond blood pressure control?. Eur Heart J 24 (2003) 504-514
25. Weiner D.E., Tighiouart H., Levey A.S., et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 18 (2007) 960-966
26. Ninomiya T., Perkovic V., Gallagher M., et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 73 (2008) 963-970
27. Committee Progress Management: PROGRESS-Perindopril Protection Against Recurrent Stroke Study: Characteristics of the study population at baseline. J Hypertens 17 (1999) 1647-1645
28. Steinmetz O.M., Panzer U., Stahl R.A.K., et al. Statin therapy in patients with chronic kidney disease: To use or not to use. Eur J Clin Invest 36 (2006) 519-527
29. Bianchi S., Bigazzi R., Caiazza A., et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565-570
30. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
31. Fellstrom B., Holdaas H., Jardine A.G., et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: Baseline data from the AURORA Study. Kidney Blood Press Res 30 (2007) 314-322
32. Baigent C., Landray M., Leaper C., et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45 (2005) 473-484
33. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 84 (2003) S207-S210
34. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299 (1978) 53-59
35. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14 (1983) 4-14
36. Farrell B., Godwin J., Richards S., et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
37. The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg of aspirin as secondary prophylaxis after cerebral vascular ischemic events. Lancet 338 (1991) 1345-1349
38. Van Gijn J., and Algra A. Secondary stroke prevention with antithrombotic drugs: What to do next?. Cerebrovasc Dis 7 (1997) 30-32
39. Algra A., and van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 66 (1996) 197-199
40. Collaboration Antithrombotic Trialists: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2000) 71-86
41. Gorelick P., and Weisman S. Risk of hemorrhagic stroke with aspirin use. An update. Stroke 36 (2005) 1801-1807
42. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
43. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
44. Kaufman J.S., O'Connor T.Z., Zhang J.H., et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14 (2003) 2313-2321
45. Best P.J.M., Steinhubl S.R., Berger P.B., et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155 (2008) 687-693
46. Diener H.C., Cunha L., Forbes C., et al. European stroke prevention study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
47. Gent M., Blakely J.A., Easton J.D., et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1 (1989) 1215-1220
48. Rothwell P.M., Eliasziw M., Gutnikov S.A., et al. Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361 (2003) 107-116
49. Barnett H.J., Taylor D.W., Eliasziw M., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 339 (1998) 1415-1425
50. Tarakji A., McConaughy A., and Nicholas G.G. The risk of carotid endarterectomy in patients with chronic renal insufficiency, current surgery. J Vasc Surg 63 (2006) 326-329
51. Ascher E., Marks N.A., Schulzer R.W., et al. Carotid endarterectomy in patients with chronic renal insufficiency: A recent series of 184 cases. J Vasc Surg 41 (2005) 24-29
52. Stoner M.C., Abbott W.M., Wong D.R., et al. Defining the high-risk patient for carotid endarterectomy: An analysis of the prospective National Surgical Quality Improvement Program database. J Vasc Surg 43 (2006) 285-295
53. Mathew A., Devereaux P.J., O'Hare A., et al. Chronic kidney disease and postoperative mortality: A systematic review and meta-analysis. Kidney Int 73 (2008) 1069-1081
54. Debing E., and Van den Brande P. Chronic renal insufficiency and risk of early mortality in patients undergoing carotid endarterectomy. Ann Vasc Surg 20 (2006) 609-613
55. Mas J.L., Chatellier G., Beyssen B., et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355 (2006) 1660-1671
56. Yadav J.S., Wholey M.H., Kuntz R.E., et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 (2004) 1493-1501
57. Bogousslavsky J., Cachin C., Regli F., et al. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: The Lausanne Stroke Registry. Neurology 41 (1991) 855-859
58. Kittner S.J., Sharkness C.M., Price T.R., et al. Infarcts with a cardiac source of embolism in NINCDS Stroke Data Bank: historical features. Neurology 40 (1990) 281-284
59. Vázquez E., Sánchez-Perales C., Borrego F., et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140 (2000) 886-890
60. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46 (2005) 897-902
61. Weisholzer M., Harm F., Tomasec G., et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21 (2001) 35-39
62. Harnett J.D., Foley R.N., Kent G.M., et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis, and risk factors. Kidney Int 47 (1993) 884-890
63. Fabbian F., Catalano C., Lambertini D., et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 54 (2000) 234-239
64. Vasquez E., Sanchez-Perales C., Lozano C., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92 (2003) 868-871
65. To A.C., Yehia M., and Collins J.F. Atrial fibrillation in haemodialysis patients: Do the guidelines for anticoagulation apply?. Nephrology 12 (2007) 441-447
66. Stroke prevention in atrial fibrillation study. Final results. Circulation 84 (1991) 527-539
67. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 348 (1996) 633-638
68. European Atrial Fibrillation Trial (EAFT) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993) 1255-1262
69. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (1999) 687-691
70. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The Boston Area Anticoagulation Trial for Atrial Fibrillation: The effect of low-dose warfarin on the risk of stoke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323 (1990) 1505-1511
71. Koos R., Mahnken A.H., Mühlenbruch G., et al. Relation of oral antiboagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 96 (2005) 747-749
72. Coates T., Kirkland G.S., Dymock R.B., et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32 (1998) 384-391
73. Bazari H., Jaff M.R., Mannstadt M., et al. Case 7-2007-A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med 356 (2007) 1049-1057